Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company's common stock, effective as of April 1, 2024. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
旧金山，2024年4月2日（环球新闻专线）——专注于女性癌症靶向疗法发现、开发和商业化的临床阶段生物制药公司奥莱玛制药公司（“Olema” 或 “Olema Oncology”，纳斯达克股票代码：OLMA）今天宣布，该公司向两名新员工授予股票期权，以购买公司总共6万股普通股，自 2024 年 4 月 1 日起生效。根据纳斯达克上市规则5635（c）（4），这些奖励已获得奥莱玛董事会薪酬委员会的批准，并根据公司的2022年激励计划发放，发放日期为2024年4月1日，作为激励新员工在奥莱玛工作的激励材料。
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $10.89 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on April 1, 2024. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
股票期权在四年内归属，25％的股票期权在归属开始日期一周年之际归属，其余部分在接下来的三年中按月等额分期归属，前提是该员工在该归属之日继续受雇于Olema。股票期权的期限为10年，行使价为每股10.89美元，等于纳斯达克于2024年4月1日公布的公司普通股最新公布的销售价格。股票期权受奥莱玛制药公司2022年激励计划的条款约束。
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
奥莱玛根据纳斯达克上市规则5635（c）（4）提供这些信息。
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .
关于 Olema Oncol
Olema Oncology是一家处于临床阶段的生物制药公司，致力于改变癌症女性的护理标准并改善其疗效。Olema利用我们对内分泌驱动的癌症、核受体和获得性耐药机制的深刻理解，正在推进一系列新疗法。除了我们的主要候选产品palazestrant（OP-1250）（一种专有的口服完全雌激素受体（ER）拮抗剂（CERAN）和选择性ER降解剂（SERD）外，Olema还在开发一种有效的KAT6抑制剂（OP-3136）。Olema 总部位于旧金山，在马萨诸塞州剑桥开展业务。欲了解更多信息，请访问我们。
Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com
联系我们:
Geoffrey Mogilner，投资者关系与传播副总裁
ir@olema.com